Heparin ointment, 25g

Heparin ointment, 25g; 'Thrombophlebitis of superficial veins (prevention and treatment); post-injection and post-infusion phlebitis; external hemorrhoids; inflammation of postpartum hemorrhoids; trophic ulcers of the leg; elephantiasis; superficial periflebitis; lymphangitis and superficial infusion; superficial mastitis; ; injuries and bruises (including muscle tissue, tendons, joints), subcutaneous hematoma.

Outwardly. The ointment is applied in a thin layer to the affected area at the rate of 0.5-1 g per area with a diameter of 3-5 cm.

Ointment for external use 1 g

heparin sodium 100 IU

benzocaine 40 mg

benzyl nicotinate 800 mcg

Hypersensitivity; ulcerative necrotic processes; violation of the integrity of the skin, children under 2 years of age.

Carefully

Thrombocytopenia, increased bleeding

pharmachologic effect

Combined drug for external use. Heparin is a direct-acting anticoagulant, belongs to the group of medium-molecular-weight heparins. When applied externally, it has a local anticoagulant, antiexudative, moderate anti-inflammatory effect. Blocks the formation of thrombin. Heparin reduces the inflammatory process and has an anticoagulant effect, indirectly improves microcirculation, which contributes to the process of resorption of hematomas and blood clots and a decrease in tissue edema. Benzocaine is a local anesthetic for surface anesthesia. By reducing the permeability of the cell membrane for sodium ions, it blocks the conduction of nerve impulses. Prevents the occurrence of pain impulses in the endings of the sensory nerves and their conduction along the nerve fibers. Benzyl nicotinate dilates superficial vessels,promoting the absorption of heparin.

Pharmacokinetics

Heparin.

Absorbed slightly. Plasma protein binding - up to 95%, Vd - 0.06 l / kg. Does not penetrate the placental barrier and into breast milk. It is intensively captured by endothelial cells and cells of the mononuclear-macrophage system, concentrated in the liver and spleen. It is metabolized in the liver by N-desulfamidase and platelet heparinase, which is included in heparin metabolism at later stages. Desulfated molecules under the influence of kidney endoglycosidase are converted into low molecular weight fragments. T1 / 2 - 1-6 hours (on average - 1.5 hours); increases with obesity, hepatic and / or renal failure; decreases with pulmonary embolism, infections, malignant tumors. It is excreted by the kidneys mainly in the form of inactive metabolites, and only when used in high doses is excretion (up to 50%) possible in an unnamed form.Not excreted by hemodialysis.

When applied externally, benzocaine is practically not absorbed. It is hydrolyzed by plasma and hepatic cholinesterase to para-aminobenzoic acid metabolites and excreted in the urine.

Side effect

Local reactions: skin flushing, allergic reactions

Application during pregnancy and lactation

Application during pregnancy and during breastfeeding is possible only if the potential benefit to the mother outweighs the risk to the fetus and child.

Application in children

Contraindicated in children under 2 years of age. Special instructions Do not apply to open wounds, mucous membranes, in the presence of purulent processes. Contact with eyes should be avoided due to possible development of irritation. In case of accidental contact with the ointment, rinse immediately with running water.

Drug interactions

Do not apply externally simultaneously with NSAIDs, tetracyclines, antihistamines.